There is evidence that brain-derived neurotropic factor (BDNF) plays a protective role in the brain. Peripheral levels of BDNF correlate with its concentration in the brain. Previous studies have revealed lower serum BDNF levels in patients with mental illnesses. In most studies serum BDNF correlates negatively with psychiatric disorders and disease severity. Most studies in this field are on psychiatric diagnosis and personality traits. The aim of our study is to explore associations between general psychiatric symptoms, independent of diagnostic groups, and serum BDNF as well as the inflammatory biomarker high-sensitive CRP (hs-CRP). Comparison between the group regularly using psychotropic medication and those not using psychotropic medication is conducted. The study is a cross sectional study with 132 participants from a general open inpatient psychiatric ward at the Nordland Hospital Trust, Bodoe, Norway. Participants were assessed on serum levels of BDNF and hs-CRP. Psychiatric symptoms were assessed by a self-rating scale (Symptom check list, SCL-90- R). Multiple linear regression model was used for statistical analyses of associations between levels of BDNF, hs-CRP and symptoms. We found a positive association (p < 0.05), for most SCL-90 symptom clusters with BDNF in the psychotropic medication-free group. No associations were found in the group of patients using psychotropic medication, except one, the paranoid ideation cluster (p 0.022). No associations were found between hs-CRP and symptom clusters. We found no relation between symptom clusters and the inflammatory biomarker hs-CRP. Serum BDNF levels were positively associated with intensity of psychiatric symptoms in the group of patients not using psychotropic medication. Our findings are in conflict with several previous studies reporting increased hs-CRP as well as decreased rather than increased BDNF in mental suffering. Patients on psychotropic medication may not require the same upregulation because the medication is modulating the underlying biological pathology.
17 July 2023 in Clinical Psychopharmacology and Neuroscience
Background: Lipids are essential in cell structure and function in all parts of the body including the brain. Thus, lipids are of obvious relevance in psychiatric disorders. While the role of lipids in pathophysiological processes in cardiovascular disorders are widely known, the role of lipids in function and pathophysiology of mental processes are far less established. This study aimed to explore serum lipid levels and their association in a clinical cohort with general psychiatric symptoms.Methods: A transdiagnostic sample of 132 patients was recruited from a general open psychiatric ward to this cross-sectional naturalistic study. Psychiatric symptoms were assessed using the Symptom Checklist-90-Revised (SCL-90-R). Serum levels of triglycerides (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were measured, and multiple linear regression analysis were performed to investigate associations with symptom clusters from SCL-90-R.Results: After correcting for the most common confounding factors, HDL was negatively associated with intensity of phobic anxiety (p=0.021), paranoid ideation (p=0.041), anger hostility (p=0.033) and interpersonal sensitivity (p=0.003) symptom clusters. No relations were found between TG, LDL and symptom clusters.Conclusion: HDL was significant inversely associated with several general psychiatric symptoms. This result indicates a role for lipids in the pathophysiology of psychiatric disorders and suggests a mechanism for the increased cardiovascular risk across psychiatric diagnoses.
11 June 2025 in Clinical Psychopharmacology and Neuroscience
Kristin Nygård-Odeh, Hedda Soløy-Nilsen, Magnhild Gangsøy-Kristiansen, Ole Lars Brekke, Tom Eirik Mollnes, Michael Berk, Jørgen Gustav Bramness. Clin Psychopharmacol Neurosci 2025;23:488-93. https://doi.org/10.9758/cpn.24.1262
Background: Psychiatric disorders and chronic hepatitis virus C infection are known to alter blood cytokines levels. However, little is known about the association between cytokines and psychiatric symptoms in patients with chronic hepatitis C virus infection. This study aimed at exploring this association. Moreover, since nearly half of the patients receive opioid maintenance treatment, we also investigated if long−term opioid treatment had any impact on these associations. Methods: We conducted a cross−sectional study on 120 outpatients referred for antiviral hepatitis C treatment. Serum level of 27 cytokines was measured using multiplex technology, and psychiatric symptom clusters were assessed using the Symptoms Check−List−90−R. Data on confounding factors including age, gender, weight, height, current medication and smoking habits were collected. Multiple linear regression analysis was performed to examine associations, adjusting for confounding factors. Results: After adjusting for the most commonly known confounding factors, IP−10 and GM−CSF were negatively associated with depression, and GM−CSF was negatively associated with phobic anxiety. Subgroup analyses revealed that these associations were present only in patients receiving opioid maintenance treatment, as demonstrated by repeated regression analysis. Conclusions: In patients with chronic hepatitis C viral infection, only IP−10 and GM−CSF were negatively associated with self−reported psychiatric symptom clusters. These associations were observed exclusively in patients receiving opioid maintenance treatment. Our study contributes to others investigations pointing to a possible immune dampening caused by long−term opioid treatment.
Background Many psychiatric disorders are linked to low grade systemic inflammation as measured by systemic cytokine levels. Exploration of cytokines and immune activity and their role in psychiatric symptoms may inform pathobiology and treatment opportunities. Methods This was a cross sectional naturalistic study with 132 participants from a general open inpatient psychiatric ward at the Nordland Hospital Trust, Norway. Serum levels of 28 different cytokines were assessed. Psychiatric symptoms the last week were assessed by a self-rating scale (Symptom check list, SCL-90- R) and grouped in defined clusters. Multiple linear regression model was used for statistical analyses of associations between levels of cytokines and symptoms, adjusting for possible confounding factors. Results We found a positive association (p0.009) between the chemokine interferon-gamma inducible protein 10(CXCL 10;IP-10) and the anger hostility cluster. No associations were found between the other symptom clusters and cytokines. IP-10 and the anger hostility cluster were positively associated (p 0.002) in the subgroup of patients using psychotropic medication, not in the subgroup not using psychotropic medication. Conclusion Our analyses revealed a significant positive association between the symptom cluster anger hostility in SCL-90-R and the chemokine IP-10 in the subgroup of patients using psychotropic medications.